A pharmacist holds a package of EpiPens, made by the pharmaceutical company Mylan. CEO Heather Bresch will testify before the House Oversight and Government Reform Committee in the coming days after Mylan jacked up the price for the lifesaving drug by more than 500 percent since 2007.
A pharmacist holds a package of EpiPens, made by the pharmaceutical company Mylan. CEO Heather Bresch will testify before the House Oversight and Government Reform Committee in the coming days after Mylan jacked up the price for the lifesaving drug by more than 500 percent since 2007. Rich Pedroncelli The Associated Press
A pharmacist holds a package of EpiPens, made by the pharmaceutical company Mylan. CEO Heather Bresch will testify before the House Oversight and Government Reform Committee in the coming days after Mylan jacked up the price for the lifesaving drug by more than 500 percent since 2007. Rich Pedroncelli The Associated Press

Editorials

September 17, 2016 8:00 AM

Drug pricing is too complex to fix with Prop. 61

Suggested for you

Comments

Videos

Editor's Choice Videos